NuWays AG Recommends Buy for Aiforia Technologies Oyj

NuWays AG has updated its recommendation for Aiforia Technologies Oyj to "BUY", with a target price of €3.80 over the next 12 months. This update follows the recent acquisition of PathAI by Roche, highlighting the growing interest in AI technology within the healthcare sector.

Aiforia Technologies, a leader in AI pathology, distinguishes itself with its pioneering AI models and a robust client base of Tier-1 clinical customers. The company's recently launched Foundation Engine is expected to accelerate profitability. In H2 2025, Aiforia's clinical revenue saw organic growth of 68% year-over-year, with projections for 2026 suggesting a 70% increase.

The ongoing consolidation in the healthtech sector underscores the commercial viability of AI technology in oncology diagnostics. Aiforia remains a prominent player in this rapidly evolving field, affirming its leading position amidst increasing industry investments in AI technology.